Clinical trials: Cervical Dysplasia
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
The goal of this observational study is to assess the five-year incidence of histologically confirmed cervical cancer among women who test positive for human papillomavirus (HPV) with low-grade cytological abnormalities, to…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
- Trial name
- NCT07259616
- Volunteers
- 46,079 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
CIN - Cervical Intraepithelial Neoplasia, HPV
Multiple Human Papillomavirus Infections in the Development of CIN
Multiple infections of high-risk genotypes of Human Papillomavirus (HR-HPV) in patients with abnormal cervical cytological or histological findings are detectable in a percentage ranging from 20% to 50% of cases.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, HPV, HPV Vaccines
- Trial name
- HPV dysplasia (NCT06862102)
- Testing
- HPV vaccine
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cervical Intraepithelial Neoplasia-II, High Risk Human Papillomavirus
Effect of Honey For CIN II
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
- Trial name
- HoneyForCINII (NCT06219018)
- Testing
- Medical grade honey formulation (MGH) (L-Mesitran®)
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Cervical Intraepithelial Neoplasia
DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2
To establish therapeutic dendritic cell (DC) vaccines targeting HPV 16/18 E6/E7 protein to block the progression of CIN1/CIN2 to cervical cancer and evaluate the safety and efficacy of the vaccines.
- Trial name
- NCT03870113
- Testing
- Vaccinated group
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
Cervical Persistent High Risk HPV Infection, Cervical Intraepithelial Neoplasia
Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
The study will examine the effect of aminolaevulinic acid (ALA) photodynamic therapy (PDT) of cervical precancerous lesions in women.
- Trial name
- NCT02304770
- Testing
- Aminolaevulinic acid photodynamic therapy
- Where
- 4 sites in China
- Volunteers
- 73 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
HIV Infections, Cervix, Dysplasia
Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors
The purpose of this study is to see if it is safe and effective to give isotretinoin to HIV-infected women with cervical tumors to prevent these tumors from becoming cancerous.
- Trial name
- NCT00001073
- Testing
- Isotretinoin
- Where
- 40 sites in United States, Puerto Rico and 1 more
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer
Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes
This study investigates the relationship between selenium levels in human tissues and the persistence of HPV (human papillomavirus) infection, particularly focusing on cervical-related lesions.
- Conditions
- Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Persistent HPV Infection
- Trial name
- SeHPV (NCT06665841)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Cervical Intraepithelial Neoplasia
A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia
This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B.
- Trial name
- NCT05502367
- Testing
- ABI-2280 Vaginal Tablet/Insert
- Where
- 7 sites in Australia, Peru and 1 more
- Volunteers
- 44 people
- Sponsor
- Antiva Biosciences
Carcinoma, Neoplasia; Intraepithelial, Cervix
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Phase II clinical trial, monocentric, not controlled, in patients with high grade cervical intraepithelial lesions. A total of 62 patients with a diagnosis of CIN II, III or carcinoma in situ will be included.
- Conditions
- Carcinoma, Neoplasia; Intraepithelial, Cervix, Glandular Neoplasms, Epithelial Neoplasm
- Trial name
- NCT03549273
- Testing
- Glizigen® + Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 62 people
- Sponsor
- Catalysis SL
Cervical Precancer
Development, Field Testing and Evaluation of the Efficacy of a Hand-held, Portable and Affordable Thermo-coagulator to Prevent Cervical Cancer in Low- and Middle-income Countries
This project develops, tests and produces a lightweight, cordless, battery driven and rechargeable hand-held device for treating cervical precancer (Liger Thermal Coagulator).
- Trial name
- DELTA (NCT02956239)
- Testing
- Thermocoagulation (device), Cryotherapy (device), LEEP (device)
- Where
- Zambia
- Volunteers
- 3,124 people
- Sponsor
- International Agency for Research on Cancer
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer Screening
Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania
This study is to analyse the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), comparing the time period before…
- Trial name
- NCT05256862
- Testing
- Data collection
- Where
- Tanzania
- Volunteers
- 2,974 people
- Sponsor
- University Hospital, Basel, Switzerland
Uterine Fibroid, Ovary Cyst
TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY
WE DECIDED TO COMPARE TWO DIFFERENT ELECTROSURGERY DEVİCES TO PROVIDE COLPOTOMY. ONE OF THEM İS MONOPOLAR HOOC, THE OTHER DEVİCE İS PLASMAKİNETİC BİPOLAR SPATULA.
- Conditions
- Uterine Fibroid, Ovary Cyst, Endometrial Hyperplasia, Cervical Dysplasia
- Trial name
- NCT04191603
- Testing
- MONOPOLAR HOOC, PLASMAKINETIC BIPOLAR SPATULA
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Alkü Alanya Education and Research Hospital
Cervical Intraepithelial Neoplasia
Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1
The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.
- Trial name
- NCT00708942
- Testing
- Hexaminolevulinate (HAL)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Photocure
Neoplasms, Cervical Adenosquamous Cell Carcinoma
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
The purpose of this phase II trial is to determine the feasibility and efficacy of nimotuzumab combined with concurrent chemoradiotherapy for initially inoperable locally advanced cervical squamous cell carcinoma.
- Conditions
- Neoplasms, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma in Situ, Stage IB Cervical Cancer
- Trial name
- NCT03469531
- Testing
- Nimotuzumab, Cisplatin, external-beam radiation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer…
- Conditions
- Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I, Cervix; Intraepithelial Neoplasia, Grade II
- Trial name
- NCT06263582
- Testing
- Artesunate pessary, blood draws for pharmacokinetics of the study drug
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center